What this means
Researchers plan to ask people about health and mood after mpox, and check immune cells and virus traces over several years. This is a study that has not reported results yet, so it cannot tell us what they found.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 18 and over
- Where
- 1 site
The science
- Registered title
- Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
- Trial ID
- NCT05879965 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Monkeypox
- Sponsor
- Institute of Tropical Medicine, Belgium
- Ages
- 18 Years to no maximum
- Dates
- First posted May 30, 2023 · updated Mar 19, 2026
Registry summary
The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine recipients.
The main questions it aims to answer are:
- Are there any physical or pschological sequelae after mpox infection?
- Is the humoral and/or cellular immune response to MPOX (or vaccinia) virus) durable?
- Do the patients develop strong local immunity in comparison to systemic immunity?
- How long is the virus still detectable in semen, saliva or the ano-rectal region?
Participants will answer a questionnaire, samples with blood, saliva and semen as well as anal swabs will be collected. Follow-up visits 8, 16 and 24, 36, 48, and 60 months after infection or vaccination are planned.
A healthy control group will be recruited in our HIV-PrEP clinic.
Sites (1)
- Institute of Tropical Medicine, Antwerp, Belgium